Recent advances in the study of CGRP receptor antagonists in migraine
10.19405/j.cnki.issn1000-1492.2025.12.023
- VernacularTitle:CGRP 受体拮抗剂在偏头痛治疗中的研究新进展
- Author:
Xiaowen Song
1
;
Bin Li
1
;
Xintong Wu
2
;
Linshan Sun
1
;
Wei Zhuang
1
Author Information
1. Dept of Neurology, Binzhou Medical University Hospital , Binzhou 256603
2. Dept of Neurology, Heze Municipal Hospital , Heze 274000
- Publication Type:Review
- Keywords:
CGRP receptor;
antagonist;
CGRP;
migraine;
triptans;
efficacy
- From:
Acta Universitatis Medicinalis Anhui
2025;60(12):2378-2384
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:Migraine is a widespread neurovascular disorder, the pathogenesis of which is closely linked to the release of calcitonin gene-related peptide(CGRP), leading to a significant impairment in patients′ quality of life. CGRP receptor antagonists exert their therapeutic effect by inhibiting the interaction between CGRP and its receptors, thereby preventing migraine attacks. Currently, several agents, including Rimegepant and Ubrogepant, have either received approval from the U. S. Food and Drug Administration or are in advanced stages of clinical trials.These drugs offer multiple advantages, such as the absence of vasoconstrictive effects, a rapid onset of action, and minimal interference with the immune system. Nevertheless, further investigation is necessary to assess their longterm safety, the potential emergence of drug resistance, and the development of individualized treatment protocols.Moreover, the integration of these novel therapies with existing treatment strategies remains a critical area for future research. This review aims to summarize recent national and international scientific advancements to establish a theoretical basis for the application of precision medicine in migraine management.
- Full text:2026030411061480725CGRP受体拮抗剂在偏头痛治疗中的研究新进展_宋晓文.pdf
